ZA955269B - Combination therapy for HIV infection - Google Patents
Combination therapy for HIV infectionInfo
- Publication number
- ZA955269B ZA955269B ZA955269A ZA955269A ZA955269B ZA 955269 B ZA955269 B ZA 955269B ZA 955269 A ZA955269 A ZA 955269A ZA 955269 A ZA955269 A ZA 955269A ZA 955269 B ZA955269 B ZA 955269B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination therapy
- hiv infection
- hiv
- infection
- therapy
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26708594A | 1994-06-27 | 1994-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA955269B true ZA955269B (en) | 1996-02-02 |
Family
ID=23017251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA955269A ZA955269B (en) | 1994-06-27 | 1995-06-26 | Combination therapy for HIV infection |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0767664A2 (xx) |
| JP (1) | JPH10503178A (xx) |
| AU (1) | AU2863895A (xx) |
| CA (1) | CA2193221A1 (xx) |
| CZ (1) | CZ375196A3 (xx) |
| FI (1) | FI965196A (xx) |
| HU (1) | HUT76546A (xx) |
| IL (1) | IL114208A0 (xx) |
| MX (1) | MX9700036A (xx) |
| NO (1) | NO965591L (xx) |
| PL (1) | PL317876A1 (xx) |
| SK (1) | SK163996A3 (xx) |
| WO (1) | WO1996000068A2 (xx) |
| ZA (1) | ZA955269B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
| PT1225874E (pt) | 1999-09-24 | 2006-06-30 | Janssen Pharmaceutica Nv | Composicoes antivirais. |
| JP6936229B2 (ja) | 2015-09-23 | 2021-09-15 | マルバーン パナリティカル リミテッド | 粒子特性評価 |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/xx unknown
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/cs unknown
- 1995-06-23 CA CA002193221A patent/CA2193221A1/en not_active Abandoned
- 1995-06-23 MX MX9700036A patent/MX9700036A/es unknown
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/en not_active Application Discontinuation
- 1995-06-23 SK SK1639-96A patent/SK163996A3/sk unknown
- 1995-06-23 JP JP8503245A patent/JPH10503178A/ja active Pending
- 1995-06-23 HU HU9603567A patent/HUT76546A/hu unknown
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-23 EP EP95923935A patent/EP0767664A2/en not_active Withdrawn
- 1995-06-23 PL PL95317876A patent/PL317876A1/xx unknown
- 1995-06-26 ZA ZA955269A patent/ZA955269B/xx unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196A/fi not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT76546A (en) | 1997-09-29 |
| CZ375196A3 (en) | 1997-07-16 |
| EP0767664A2 (en) | 1997-04-16 |
| WO1996000068A2 (en) | 1996-01-04 |
| PL317876A1 (en) | 1997-04-28 |
| HU9603567D0 (en) | 1997-02-28 |
| AU2863895A (en) | 1996-01-19 |
| FI965196A0 (fi) | 1996-12-23 |
| SK163996A3 (en) | 1997-08-06 |
| WO1996000068A3 (en) | 1996-02-22 |
| MX9700036A (es) | 1997-04-30 |
| NO965591D0 (no) | 1996-12-27 |
| CA2193221A1 (en) | 1996-01-04 |
| IL114208A0 (en) | 1995-10-31 |
| JPH10503178A (ja) | 1998-03-24 |
| NO965591L (no) | 1996-12-27 |
| FI965196A (fi) | 1996-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0707855A3 (en) | Combination therapy for chronic hepatitis C infection | |
| AP9700951A0 (en) | Medicaments | |
| GB9411080D0 (en) | Treatment | |
| ZA957879B (en) | Combination therapy for hypercholesterolemia | |
| AU7973994A (en) | Combination therapy for hiv infection | |
| GB9406573D0 (en) | Medicaments | |
| ZA9533B (en) | Pentolifylline therapy | |
| HRP960045B1 (en) | Combination therapy for hiv infection | |
| HU9603567D0 (en) | Combination therapy for hiv infection | |
| IL114415A0 (en) | Anti-HIV triple therapeutic combination | |
| GB9408084D0 (en) | Medical treatment | |
| GB9411052D0 (en) | Medicaments | |
| ZA956662B (en) | Combination therapy for HIV infection | |
| AU1925295A (en) | Ribozyme therapy for hepatitis b infection | |
| EP0724882A4 (en) | NEW DRUGS AGAINST HIV | |
| EP0790829A4 (en) | DRUG | |
| GB9420703D0 (en) | Medicament | |
| GB9419954D0 (en) | Medicament | |
| GB9408693D0 (en) | Medicament | |
| GB9400159D0 (en) | Medicament solution | |
| GB9418077D0 (en) | Medical aid | |
| GB9708380D0 (en) | HIV treatment | |
| GB9701117D0 (en) | HIV Treatment | |
| GB9420340D0 (en) | Therapeutic improvement | |
| GB9404379D0 (en) | Therapeutic improvement |